Reduced susceptibility to chlorhexidine in staphylococci: Is it increasing and does it matter?

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 11, 2012, Pages 2547-2559

  Horner, Carolyne ^a   Mawer, Damien ^a   Wilcox, Mark ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Antiseptic; Biocide; Resistance; Staphylococcus aureus

Indexed keywords

BIOCIDE; CHLORHEXIDINE; PSEUDOMONIC ACID;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BIOFILM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENETIC RESISTANCE; HAND WASHING; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PHENOTYPE; PREVALENCE; REVIEW; SKIN FLORA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

ANTI-INFECTIVE AGENTS, LOCAL; CHLORHEXIDINE; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; HUMANS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; STAPHYLOCOCCUS;

EID: 84867587100     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks284     Document Type: Review

References (107)

1. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev 1999; 12: 147-79.
2. Scientific Committee on Consumer Products. Opinion on Triclosan. http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf (13 May 2012, date last accessed).
3. Scientific Committee on Consumer Products. Opinion on Triclosan (Antimicrobial Resistance). http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_023.pdf (13 May 2012, date last accessed).
4. HPA. Quarterly Epidemiological Commentaries on MRSA, MSSA, Escherichia coli Bacteraemia and C. difficile Infection. http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1259151891722 (26 April 2012, date last accessed).
5. Bode LG, Kluytmans JA, Wertheim HF et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med 2010; 362: 9-17.
6. Walker EM, Lowes JA. An investigation into in vitro methods for the detection of chlorhexidine resistance. J Hosp Infect 1985; 6: 389-97.
7. Walsh SE, Maillard JY, Russell AD et al. Development of bacterial resistance to several biocides and effects on antibiotic susceptibility. J Hosp Infect 2003; 55: 98-107.
8. Noguchi N, Hase M, Kitta M et al. Antiseptic susceptibility and distribution of antiseptic-resistance genes in methicillin-resistant Staphylococcus aureus. FEMS Microbiol Lett 1999; 172: 247-53.
9. Sekiguchi J, Hama T, Fujino T et al. Detection of the antiseptic- and disinfectant-resistance genes qacA, qacB, and qacC in methicillin-resistant Staphylococcus aureus isolated in a Tokyo hospital. Jpn J Infect Dis 2004; 57: 288-91.
10. Zmantar T, Kouidhi B, Miladi H et al. Detection of macrolide and disinfectant resistance genes in clinical Staphylococcus aureus and coagulase-negative staphylococci. BMC Res Notes 2011; 4: 453.
11. Chapman JS. Disinfectant resistance mechanisms, cross-resistance, and co-resistance. Int Biodeter Biodegr 2003; 51: 271-6.
12. Maillard JY. Bacterial resistance to biocides in the healthcare environment: should it beof genuine concern? JHosp Infect 2007;65: 60-72.
13. Meyer B, Cookson B. Does microbial resistance or adaptation to biocides create a hazard in infection prevention and control? J Hosp Infect 2010; 76: 200-5.
14. Russell AD. Introduction of biocides into clinical practice and the impact on antibiotic-resistant bacteria. Symp Ser Soc Appl Microbiol 2002; 92: 121S-35S.
15. Scientific Committee on Emerging and Newly Identified Health Risks. Assessment of the Antibiotic Resistance Effects of Biocides. 2009. http://ec.europa.eu/health/ph-risk/committees/04-scenihr/docs/scenihr_o_021.pdf (11 July 2012, date last accessed).
16. Davies GE, Francis J, Martin AR et al. 1:6-Di-4'-chlorophenyldiguanidohexane (hibitane); laboratory investigation of a new antibacterial agent of high potency. Br J Pharmacol Chemother 1954; 9: 192-6.
17. Russell AD. Chlorhexidine: antibacterial action and bacterial resistance. Infection 1986; 14: 212-5.
18. Milstone AM, Passaretti CL, Perl TM. Chlorhexidine: expanding the armamentarium for infection control and prevention. Clin Infect Dis 2008; 46: 274-81.
19. Hugo WB, Longworth AR. Some aspects of the mode of action of chlorhexidine. J Pharm Pharmacol 1964; 16: 655-62.
20. Gilbert P, Moore LE. Cationic antiseptics: diversity of action under a common epithet. J Appl Microbiol 2005; 99: 703-15.
21. Denton GW. Chlorhexidine. In: Block SS, ed. Disinfection, Sterilization, and Preservation. Philadelphia: Lippincott Williams and Wilkins, 2001; 321-36.
22. Kampf G, Kramer A. Epidemiologic background of hand hygiene and evaluation of the most important agents for scrubs and rubs. Clin Microbiol Rev 2004; 17: 863-93.
23. Russell AD, Day MJ. Antibacterial activity of chlorhexidine. J Hosp Infect 1993; 25: 229-38.
24. Boyce JM, Pittet D. Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HIPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Am J Infect Control 2002; 30: S1-46.
25. WHO. Guidelines on Hand Hygiene in Healthcare. 2009. http://whqlibdoc.who.int/publications/2009/9789241597906_eng.pdf (11 July 2012, date last accessed).
26. Lowbury EJ, Lilly HA. Use of 4 per cent chlorhexidine detergent solution (Hibiscrub) and other methods of skin disinfection. Br Med J 1973; 1: 510-5.
27. Joint Formulary Committee. British National Formulary. http://www.bnf.org (15 June 2012, date last accessed).
28. Department of Health. High Impact Intervention: Care Bundle to Prevent Surgical Site Infection. http://hcai.dh.gov.uk/files/2011/03/2011-03-14-HII-Prevent-Surgical-Site-infection-FINAL.pdf (27 March 2012, date last accessed).
29. Department of Health. High Impact Intervention: Peripheral Venous Cannula Care Bundle. http://hcai.dh.gov.uk/files/2011/03/2011-03-14-HII-Peripheral-intravenous-cannula-bundle-FIN%E2%80%A6.pdf (27 March 2012, date last accessed).
30. Department of Health. High Impact Intervention: Central Venous Catheter Care Bundle. http://hcai.dh.gov.uk/files/2011/03/2011-03-14-HII-Central-Venous-Catheter-Care-Bundle-FINAL.pdf (27 March 2012, date last accessed).
31. Coia JE, Duckworth GJ, Edwards DI et al. Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect 2006; 63 Suppl 1: S1-44.
32. Peterson AF, Rosenberg A, Alatary SD. Comparative evaluation of surgical scrub preparations. Surg Gynecol Obstet 1978; 146: 63-5.
33. Aly R, Maibach HI. Comparative antibacterial efficacy of a 2-minute surgical scrub with chlorhexidine gluconate, povidone-iodine, and chloroxylenol sponge-brushes. Am J Infect Control 1988; 16: 173-7.
34. Kampf G. What is left to justify the use of chlorhexidine in hand hygiene? J Hosp Infect 2008; 70 Suppl 1: 27-34.
35. Reichel M, Heisig P, Kampf G. Pitfalls in efficacy testing-how important is the validation of neutralization of chlorhexidine digluconate? Ann Clin Microbiol Antimicrob 2008; 7: 20.
36. Rosenberg A, Alatary SD, Peterson AF. Safety and efficacy of the antiseptic chlorhexidine gluconate. Surg Gynecol Obstet 1976; 143: 789-92.
37. Larson E, Friedman C, Cohran J et al. Prevalence and correlates of skin damage on the hands of nurses. Heart Lung 1997; 26: 404-12.
38. Sijbesma T, Rockmann H, van der Weegen W. Severe anaphylactic reaction to chlorhexidine during total hip arthroplasty surgery. A case report. Hip Int 2011; 21: 630-2.
39. Lai P, Coulson C, Pothier DD et al. Chlorhexidine ototoxicity in ear surgery, part 1: review of the literature. J Otolaryngol Head Neck Surg 2011; 40: 437-40.
40. Mullany LC, Darmstadt GL, Tielsch JM. Safety and impact of chlorhexidine antisepsis interventions for improving neonatal health in developing countries. Pediatr Infect Dis J 2006; 25: 665-75.
41. Russell AD. Bacterial resistance to disinfectants: present knowledge and future problems. J Hosp Infect 1999; 43 Suppl: S57-68.
42. Paulsen IT, Brown MH, Skurray RA. Proton-dependent multidrug efflux systems. Microbiol Rev 1996; 60: 575-608.
43. Russell AD. Do biocides select for antibiotic resistance? J Pharm Pharmacol 2000; 52: 227-33.
44. Platt JH, Bucknall RA. MIC tests are not suitable for assessing antiseptic handwashes. J Hosp Infect 1988; 11: 396-7.
45. Wiegand I, Hilpert K, Hancock RE. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 2008; 3: 163-75.
46. Alam MM, Kobayashi N, Uehara N et al. Analysis on distribution and genomic diversity of high-level antiseptic resistance genes qacA and qacB in human clinical isolates of Staphylococcus aureus. Microb Drug Resist 2003; 9: 109-21.
47. Sheng WH, Wang JT, Lauderdale TL et al. Epidemiology and susceptibilities of methicillin-resistant Staphylococcus aureus in Taiwan: emphasis on chlorhexidine susceptibility. Diagn Microbiol Infect Dis 2009; 63: 309-13.
48. Wang JT, Sheng WH, Wang JL et al. Longitudinal analysis of chlorhexidine susceptibilities of nosocomial methicillin-resistant Staphylococcus aureus isolates at a teaching hospital in Taiwan. J Antimicrob Chemother 2008; 62: 514-7.
49. Vali L, Davies SE, Lai LL et al. Frequency of biocide resistance genes, antibiotic resistance and the effect of chlorhexidine exposure on clinical methicillin-resistant Staphylococcus aureus isolates. J Antimicrob Chemother 2008; 61: 524-32.
50. Suller MT, Russell AD. Antibiotic and biocide resistance in methicillinresistant Staphylococcus aureus and vancomycin-resistant Enterococcus. J Hosp Infect 1999; 43: 281-91.
51. Brill F, Goroncy-Bermes P, Sand W. Influence of growth media on the sensitivity of Staphylococcus aureus and Pseudomonas aeruginosa to cationic biocides. Int J Hyg Environ Health 2006; 209: 89-95.
52. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44: 1208-15.
53. Littlejohn TG, Paulsen IT, Gillespie MT et al. Substrate specificity and energetics of antiseptic and disinfectant resistance in Staphylococcus aureus. FEMS Microbiol Lett 1992; 74: 259-65.
54. Mitchell BA, Brown MH, Skurray RA. qacA multidrug efflux pump from Staphylococcus aureus: comparative analysis of resistance to diamidines, biguanidines, and guanylhydrazones. Antimicrob Agents Chemother 1998; 42: 475-7.
55. Littlejohn TG, DiBerardino D, Messerotti LJ et al. Structure and evolution of a family of genes encoding antiseptic and disinfectant resistance in Staphylococcus aureus. Gene 1991; 101: 59-66.
56. Rouch DA, Cram DS, DiBerardino D et al. Efflux-mediated antiseptic resistance gene qacA from Staphylococcus aureus: common ancestry with tetracycline- and sugar-transport proteins. Mol Microbiol 1990; 4: 2051-62.
57. Tennent JM, Lyon BR, Midgley M et al. Physical and biochemical characterization of the qacA gene encoding antiseptic and disinfectant resistance in Staphylococcus aureus. J Gen Microbiol 1989; 135: 1-10.
58. Leelaporn A, Paulsen IT, Tennent JM et al. Multidrug resistance to antiseptics and disinfectants in coagulase-negative staphylococci. J Med Microbiol 1994; 40: 214-20.
59. Kastbjerg VG, Larsen MH, Gram L et al. Influence of sublethal concentrations of common disinfectants on expression of virulence genes in Listeria monocytogenes. Appl Environ Microbiol 2010; 76: 303-9.
60. Coenye T, Van AH, Peeters E et al. Molecular mechanisms of chlorhexidine tolerance in Burkholderia cenocepacia biofilms. Antimicrob Agents Chemother 2011; 55: 1912-9.
61. Noguchi N, Suwa J, Narui K et al. Susceptibilities to antiseptic agents and distribution of antiseptic-resistance genes qacA/B and smr of methicillin-resistant Staphylococcus aureus isolated in Asia during 1998 and 1999. J Med Microbiol 2005; 54: 557-65.
62. Zhang M, O'Donoghue MM, Ito T et al. Prevalence of antisepticresistance genes in Staphylococcus aureus and coagulase-negative staphylococci colonising nurses and the general population in Hong Kong. J Hosp Infect 2011; 78: 113-7.
63. DeMarco CE, Cushing LA, Frempong-Manso E et al. Efflux-related resistance to norfloxacin, dyes, and biocides in bloodstream isolates of Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 3235-9.
64. Paulsen IT, Brown MH, Littlejohn TG et al. Multidrug resistance proteins QacA and QacB from Staphylococcus aureus: membrane topology and identification of residues involved in substrate specificity. Proc Natl Acad Sci USA 1996; 93: 3630-5.
65. Lyon BR, Skurray R. Antimicrobial resistance of Staphylococcus aureus: genetic basis. Microbiol Rev 1987; 51: 88-134.
66. Noguchi N, Nakaminami H, Nishijima S et al. Antimicrobial agent of susceptibilities and antiseptic resistance gene distribution among methicillin-resistant Staphylococcus aureus isolates from patients with impetigo and staphylococcal scalded skin syndrome. J Clin Microbiol 2006; 44: 2119-25.
67. International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements. Classification of staphylococcal cassette chromosome mec (SCCmec): guidelines for reporting novel SCCmec elements. Antimicrob Agents Chemother 2009; 53: 4961-7.
68. Anthonisen IL, Sunde M, Steinum TM et al. Organization of the antiseptic resistance gene qacA and Tn552-related β-lactamase genes in multidrug-resistant Staphylococcus haemolyticus strains of animal and human origins. Antimicrob Agents Chemother 2002; 46: 3606-12.
69. McGann P, Kwak YI, Summers A et al. Detection of qacA/B in clinical isolates of methicillin-resistant Staphylococcus aureus from a regional healthcare network in the eastern United States. Infect Control Hosp Epidemiol 2011; 32: 1116-9.
70. Miyazaki NH, Abreu AO, Marin VA et al. The presence of qacA/B gene in Brazilian methicillin-resistant Staphylococcus aureus. Mem Inst Oswaldo Cruz 2007; 102: 539-40.
71. Sidhu MS, Heir E, Leegaard T et al. Frequency of disinfectant resistance genes and genetic linkage with β-lactamase transposon Tn552 among clinical staphylococci. Antimicrob Agents Chemother 2002; 46: 2797-803.
72. Mayer S, Boos M, Beyer A et al. Distribution of the antiseptic resistance genes qacA, qacB and qacC in 497 methicillin-resistant and -susceptible European isolates of Staphylococcus aureus. J Antimicrob Chemother 2001; 47: 896-7.
73. Nakaminami H, Noguchi N, Nishijima S et al. Transduction of the plasmid encoding antiseptic resistance gene qacB in Staphylococcus aureus. Biol Pharm Bull 2007; 30: 1412-5.
74. Longtin J, Seah C, Siebert K et al. Distribution of antiseptic resistance genes qacA, qacB, and smr in methicillin-resistant Staphylococcus aureus isolated in Toronto, Canada, from 2005 to 2009. Antimicrob Agents Chemother 2011; 55: 2999-3001.
75. Smith K, Gemmell CG, Hunter IS. The association between biocide tolerance and the presence or absence of qac genes among hospital-acquired and community-acquired MRSA isolates. J Antimicrob Chemother 2008; 61: 78-84.
76. Lee AS, Macedo-Vinas M, Francois P et al. Impact of combined low-level mupirocin and genotypic chlorhexidine resistance on persistent methicillin-resistant Staphylococcus aureus carriage after decolonization therapy: a case-control study. Clin Infect Dis 2011; 52: 1422-30.
77. Ellington MJ, Hope R, Livermore DM et al. Decline of EMRSA-16 amongst methicillin-resistant Staphylococcus aureus causing bacteraemias in the UK between 2001 and 2007. J Antimicrob Chemother 2010; 65: 446-8.
78. Kampf G, Jarosch R, Ruden H. Limited effectiveness of chlorhexidine based hand disinfectants against methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect 1998; 38: 297-303.
79. Wootton M, Walsh TR, Davies EM et al. Evaluation of the effectiveness of common hospital hand disinfectants against methicillin-resistant Staphylococcus aureus, glycopeptide-intermediate S. aureus, and heterogeneous glycopeptide-intermediate S. aureus. Infect Control Hosp Epidemiol 2009; 30: 226-32.
80. Cookson BD, Bolton MC, Platt JH. Chlorhexidine resistance in methicillin-resistant Staphylococcus aureus or just an elevated MIC? An in vitro and in vivo assessment. Antimicrob Agents Chemother 1991; 35: 1997-2002.
81. Block C, Furman M. Association between intensity of chlorhexidine use and micro-organisms of reduced susceptibility in a hospital environment. J Hosp Infect 2002; 51: 201-6.
82. Batra R, Cooper BS, Whiteley C et al. Efficacy and limitation of a chlorhexidine-based decolonization strategy in preventing transmission of methicillin-resistant Staphylococcus aureus in an intensive care unit. Clin Infect Dis 2010; 50: 210-7.
83. Harbarth S, Dharan S, Liassine N et al. Randomized, placebocontrolled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 1412-6.
84. Kassakian SZ, Mermel LA, Jefferson JA et al. Impact of chlorhexidine bathing on hospital-acquired infections among general medical patients. Infect Control Hosp Epidemiol 2011; 32: 238-43.
85. Simor AE, Phillips E, McGeer A et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillinresistant Staphylococcus aureus colonization. Clin Infect Dis 2007; 44: 178-85.
86. Wendt C, Schinke S, Wurttemberger M et al. Value of whole-body washing with chlorhexidine for the eradication of methicillin-resistant Staphylococcus aureus: a randomized, placebo-controlled, double-blind clinical trial. Infect Control Hosp Epidemiol 2007; 28: 1036-43.
87. Ridenour G, Lampen R, Federspiel J et al. Selective use of intranasal mupirocin and chlorhexidine bathing and the incidence of methicillinresistant Staphylococcus aureus colonization and infection among intensive care unit patients. Infect Control Hosp Epidemiol 2007; 28: 1155-61.
88. Maki DG. The use of antiseptics for handwashing by medical personnel. J Chemother 1989; 1 Suppl 1: 3-11.
89. Smylie HG, Logie JR, Smith G. From Phisohex to Hibiscrub. Br Med J 1973; 4: 586-9.
90. Mangram AJ, Horan TC, Pearson ML et al. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999; 20: 250-78.
91. Chaiyakunapruk N, Veenstra DL, Lipsky BA et al. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med 2002; 136: 792-801.
92. ClimoMW, Sepkowitz KA, ZuccottiGet al. The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and healthcare-associated bloodstream infections: results of a quasi-experimental multicenter trial. Crit Care Med 2009; 37: 1858-65.
93. Parras F, Guerrero MC, Bouza E et al. Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 175-9.
94. Timsit JF, Schwebel C, Bouadma L et al. Chlorhexidine-impregnated sponges and less frequent dressing changes for prevention of catheterrelated infections in critically ill adults: a randomized controlled trial. JAMA 2009; 301: 1231-41.
95. Brun-Buisson C, Doyon F, Sollet JP et al. Prevention of intravascular catheter-related infection with newer chlorhexidine-silver sulfadiazinecoated catheters: a randomized controlled trial. Intens Care Med 2004; 30: 837-43.
96. Ostendorf T, Meinhold A, Harter C et al. Chlorhexidine and silversulfadiazine coated central venous catheters in haematological patients-a double-blind, randomised, prospective, controlled trial. Support Care Cancer 2005; 13: 993-1000.
97. Rupp ME, Lisco SJ, Lipsett PA et al. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. Ann Intern Med 2005; 143: 570-80.
98. Bassetti S, Hu J, D'Agostino RB Jr. et al. Prolonged antimicrobial activity of a catheter containing chlorhexidine-silver sulfadiazine extends protection against catheter infections in vivo. Antimicrob Agents Chemother 2001; 45: 1535-8.
99. Chlebicki MP, Safdar N. Topical chlorhexidine for prevention of ventilator-associated pneumonia: a meta-analysis. Crit Care Med 2007; 35: 595-602.
100. Kucken D, Feucht H, Kaulfers P. Association of qacE and qacED1 with multiple resistance to antibiotics and antiseptics in clinical isolates of Gram-negative bacteria. FEMS Microbiol Lett 2000; 183: 95-8.
101. Kazama H, Hamashima H, Sasatsu M et al. Distribution of the antiseptic-resistance gene qacED1 in Gram-positive bacteria. FEMS Microbiol Lett 1998; 165: 295-9.
102. Ploy MC, Courvalin P, Lambert T. Characterization of In40 of Enterobacter aerogenes BM2688, a class 1 integron with two new gene cassettes, cmlA2 and qacF. Antimicrob Agents Chemother 1998; 42: 2557-63.
103. Heir E, Sundheim G, Holck AL. The qacG gene on plasmid pST94 confers resistance to quaternary ammonium compounds in staphylococci isolated from the food industry. J Appl Microbiol 1999; 86: 378-88.
104. Heir E, Sundheim G, Holck AL. The Staphylococcus qacH gene product: a new member of the SMR family encoding multidrug resistance. FEMS Microbiol Lett 1998; 163: 49-56.
105. Bjorland J, Steinum T, Sunde M et al. Novel plasmid-borne gene qacJ mediates resistance to quaternary ammonium compounds in equine Staphylococcus aureus, Staphylococcus simulans, and Staphylococcus intermedius. Antimicrob Agents Chemother 2003; 47: 3046-52.
106. Braga TM, Marujo PE, Pomba C et al. Involvement, and dissemination, of the enterococcal small multidrug resistance transporter QacZ in resistance to quaternary ammonium compounds. J Antimicrob Chemother 2011; 66: 283-6.
107. Wang C, Cai P, Zhan Q et al. Distribution of antiseptic-resistance genes qacA/B in clinical isolates of meticillin-resistant Staphylococcus aureus in China. J Hosp Infect 2008; 69: 393-4..